Focus on cardiotoxicity and its prevention in patients with cancer diseases

Research relevance: currently, in many less developed countries, including Kyrgyzstan, cardioprotection has not previously been performed in cancer patients receiving chemotherapy, which should be given special attention. If patient has a pre-existing cardiovascular disease, then the heart disease should first be corrected before chemotherapy or radiotherapy is started. Research objectives: determination of cardio and antitumor drugs effect on cardiotoxicity and cardioprotective efficacy of some beta-blockers when used in patients undergoing chemotherapy. Research materials and methods: risk assessment of cardiotoxicity drugs used in chemotherapy, classification of cardiotoxicity and cardiovascular toxicity according to signs. Research results: considering the growth of malignant diseases, this industry needs to be developed in order to improve patients’ quality of life, as well as to reduce the mortality of the latter from cardiovascular complications associated with toxic myocardial damage. Conclusion: cardio-oncology is a really new and promising specialty that requires large, randomized trials in our country.